Recently, three patients from the same family were granted a life-saving experimental therapy.
The results were astounding.
The results of this small study indicate 100% effectiveness in reducing the targeted protein which causes polymerization (and precipitation) of amyloid fibrils, the very same material that causes the plaque found in the cerebral arteries of Alzheimer's patients.
Our lead re-purposing compound has been shown to be safe and well tolerated when taken orally.
We are now expanding to a larger clinical trial to establish a proof of concept.